Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Federal judge orders Jefferson County to redraw racially gerrymandered districts
U.S. District Judge Madeline H. Haikala ruled the county map was unconstitutional because race was the predominant factor when the Jefferson County Commission drew districts.
Why beef prices are higher than ever (and shoppers are finally resisting)
American ranchers are raising the fewest cows in decades. Through the price increases, American shoppers have stayed loyal to their love of burgers and steaks — until now.
ABC pulls Jimmy Kimmel off air after comments made about the Charlie Kirk killing
ABC announced Wednesday that Jimmy Kimmel Live! would be off the air indefinitely following comments regarding speculation swirling around the suspect in the killing of Charlie Kirk.
What does the Google antitrust ruling mean for the future of AI?
A federal judge's mild ruling in the Justice Department's suit over Google's search engine monopoly has critics worried that the tech giant can now monopolize artificial intelligence.
Trump is deploying the National Guard to Memphis. Experts worry it’s becoming normal
The president signed an order earlier this week to send Tennessee state National Guard troops, along with officials from various federal departments and agencies, into Memphis, in an effort to fight crime. It's one of several U.S. cities Trump has singled out for such a move, testing the limits of presidential power and military force.
CDC’s vaccine advisers meet this week. Here’s how they could affect policy
Health Secretary Robert F. Kennedy, Jr. chose everyone in the group. Their votes could affect vaccine access for certain childhood vaccines and and the COVID shots. Here's what's at stake.
